Yuval Harari - Bio View Co-CEO, Director
| BIOV Stock | ILS 28.60 0.30 1.04% |
CEO
Mr. Yuval Harari no longer serves as Executive Vice President and Director at BioView Ltd, but rather as Executive Vice President, effective January 1, 2016. He held the role of Executive Vice President and Director at the Company since April 7, 2009. Previously he served as Vice President of Product Development at the Company . He is one of the Companys CoFounders. His work experience includes the following roles Software Engineering Manager at Neuromedical Systems Israel and Research Fellow at the IBM Research Lab . He holds a BS degree and a MS degree, both in Computer Science from The Hebrew University of Jerusalem. since 2016.
| Age | 53 |
| Tenure | 8 years |
| Phone | 972 73 227 1025 |
| Web | https://www.bioview.com |
Bio View Management Efficiency
Bio View's management efficiency ratios could be used to measure how well Bio View manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 3 records | CEO Age | ||
| Kinneret Savitsky | BioLine RX | 48 | |
| Shai Meretzki | Bonus Biogroup | 54 | |
| Anat CohenDayag | Compugen | 56 | |
Management Performance
| Return On Equity | 0.0399 | |||
| Return On Asset | 0.0091 |
Bio View Leadership Team
Elected by the shareholders, the Bio View's board of directors comprises two types of representatives: Bio View inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bio. The board's role is to monitor Bio View's management team and ensure that shareholders' interests are well served. Bio View's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bio View's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Elad Kfir, Vice President of Marketing | ||
| Eliane Markowitz, External Director | ||
| Yuval Harari, Co-CEO, Director | ||
| Emmanuel Gill, Chairman of the Board | ||
| David Kutas, CEO of BioView Inc - USA and President of BioView Inc - USA | ||
| Yacha Sutton, Director | ||
| Marina Wolfson, CFO | ||
| Alan Schwebel, CEO and Pres | ||
| Jackie RosenblumGoren, External Director | ||
| Yulia CPA, Chief Officer | ||
| Inbal Hillel, Vice President - Operations | ||
| Lior Shav, Director | ||
| Yuval MSc, Ex VP | ||
| Eliyahu AyalonLanciano, External Director | ||
| Warren Esanu, Director |
Bio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bio View a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0399 | |||
| Return On Asset | 0.0091 | |||
| Profit Margin | 0.04 % | |||
| Operating Margin | 0.02 % | |||
| Current Valuation | 35.4 M | |||
| Shares Outstanding | 13.75 M | |||
| Shares Owned By Insiders | 51.58 % | |||
| Price To Book | 1.72 X | |||
| Price To Sales | 1.71 X | |||
| Revenue | 30.51 M |
Pair Trading with Bio View
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bio View position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bio View will appreciate offsetting losses from the drop in the long position's value.Moving together with Bio Stock
| 0.61 | GIVO-L | GIVOT OLAM OIL | PairCorr |
Moving against Bio Stock
| 0.57 | SAFE | Safe T Group | PairCorr |
| 0.57 | BMDX | Biomedix Incubator | PairCorr |
| 0.46 | BSP | Black Sea Property | PairCorr |
| 0.46 | ICB | Israel China Biotech | PairCorr |
The ability to find closely correlated positions to Bio View could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bio View when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bio View - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bio View to buy it.
The correlation of Bio View is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bio View moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bio View moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bio View can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio View. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Complementary Tools for Bio Stock analysis
When running Bio View's price analysis, check to measure Bio View's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio View is operating at the current time. Most of Bio View's value examination focuses on studying past and present price action to predict the probability of Bio View's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio View's price. Additionally, you may evaluate how the addition of Bio View to your portfolios can decrease your overall portfolio volatility.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |